跳至主要内容
临床试验/NCT00804479
NCT00804479终止不适用

Unblinded, Multicenter, Prospective Follow-up of Long-term Consequences of Initiating Patients With Parkinson's Disease on Either Pramipexole or Levodopa.

University of Rochester1 个研究点 分布在 1 个国家目标入组 222 人开始时间: 2002年1月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
222
试验地点
1
主要终点
We hypothesize that patients initiating therapy with pramipexole compared with levodopa will demonstrate less self-reported disability as measured by the Modified Schwab and England.

研究概览

简要总结

To determine the long-term consequences (8 years) of initiating patients with Parkinson's disease on either pramipexole or levodopa. We hypothesize that patients initiating therapy with pramipexole compared with levodopa will demonstrate less self-reported disability as measured by the Modified Schwab and England (S/E) scale 8 years after randomization.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Available 301 subjects enrolled in the CALM-PD study.

排除标准

  • Those not enrolled in the CALM-PD study.

结局指标

主要结局

We hypothesize that patients initiating therapy with pramipexole compared with levodopa will demonstrate less self-reported disability as measured by the Modified Schwab and England.

时间窗: 8 years from date randomized in CALM study

次要结局

  • Our secondary specific aim is to develop and estimate a structural model that will allow us to uncover the causal pathways through which treatments effect outcomes.(8 years from randomization of CALM-PD study)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Robert Holloway

Professor

University of Rochester

研究点 (1)

Loading locations...

相似试验